TrialCancer immunology, immunotherapy : CII2023
Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma.
Guru P Sonpavde et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
10 papers cite it
this paperpooled ittrialcites it